Skip to main content

Vistagen Therapeutics, Inc.

VTGN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001411685

No open-market purchases or sales by Vistagen Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $2.54M in total; no superinvestor holds it.

13F holders, Q3 2024

Institutional positions in Vistagen Therapeutics, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
47
+5 vs. Q2 2024
Shares held
15.3M
−674.7K (−4.2%) vs. Q2 2024
Total value
$45.3M
−$9.60M (−17.5%) vs. Q2 2024
New holders
8
9 more added
Sold out
3
13 more reduced

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q2 2024: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting VTGN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ3 2024: 47 institutions
Q1 2021: 74 institutionsQ2 2021: 101 institutionsQ3 2021: 105 institutionsQ4 2021: 106 institutionsQ1 2022: 116 institutionsQ2 2022: 112 institutionsQ3 2022: 93 institutionsQ4 2022: 86 institutionsQ1 2023: 83 institutionsQ2 2023: 33 institutionsQ3 2023: 34 institutionsQ4 2023: 46 institutionsQ1 2024: 42 institutionsQ2 2024: 43 institutionsQ3 2024: 47 institutionsQ4 2024: 54 institutionsQ1 2025: 48 institutionsQ2 2025: 51 institutionsQ3 2025: 58 institutionsQ4 2025: 55 institutionsQ1 2026: 56 institutionsQ2 2026: 48 institutions
Value heldQ3 2024: $45.3M
Q1 2021: $225.2MQ2 2021: $389.0MQ3 2021: $360.2MQ4 2021: $269.2MQ1 2022: $167.8MQ2 2022: $122.1MQ3 2022: $9.13MQ4 2022: $4.15MQ1 2023: $4.79MQ2 2023: $1.82MQ3 2023: $15.7MQ4 2023: $90.0MQ1 2024: $90.8MQ2 2024: $56.3MQ3 2024: $45.3MQ4 2024: $44.9MQ1 2025: $39.0MQ2 2025: $30.3MQ3 2025: $81.8MQ4 2025: $8.84MQ1 2026: $8.12MQ2 2026: $2.54M
Institutions holding VTGN and their total value by quarter
QuarterHoldersValue
Q2 202648$2.54M
Q1 202656$8.12M
Q4 202555$8.84M
Q3 202558$81.8M
Q2 202551$30.3M
Q1 202548$39.0M
Q4 202454$44.9M
Q3 202447$45.3M
Q2 202443$56.3M
Q1 202442$90.8M
Q4 202346$90.0M
Q3 202334$15.7M
Q2 202333$1.82M
Q1 202383$4.79M
Q4 202286$4.15M
Q3 202293$9.13M
Q2 2022112$122.1M
Q1 2022116$167.8M
Q4 2021106$269.2M
Q3 2021105$360.2M
Q2 2021101$389.0M
Q1 202174$225.2M

Institutions, Q3 2024

Shares, value and share of portfolio for each institution holding Vistagen Therapeutics, Inc.; share changes are against Q2 2024.

Institutions holding VTGN in Q3 2024
InstitutionSharesValue% of portfolioChange in sharesAction
TCG Crossover Management, LLC2,676,580$8.06M0.68%00.0%Unchanged
BVF Inc2,000,000$6.02M0.18%00.0%Unchanged
Vanguard Group Inc1,793,166$5.40M0.00%00.0%Unchanged
StemPoint Capital LP1,846,792$4.90M1.47%−1,790−0.1%Reduced
Commodore Capital LP1,575,000$4.74M0.30%00.0%Unchanged
Nantahala Capital Management, LLC1,517,696$4.57M0.38%00.0%Unchanged
Sphera Funds Management Ltd.808,550$2.43M0.40%00.0%Unchanged
Great Point Partners LLC674,075$2.03M0.61%−855,263−55.9%Reduced
BlackRock, Inc.412,129$1.24M0.00%+412,129New
Citadel Advisors LLC321,885$968.9K0.00%−307,760−48.9%Reduced
Geode Capital Management, LLC258,524$778.4K0.00%−31,570−10.9%Reduced
Renaissance Technologies LLC190,600$573.7K0.00%+125,700+193.7%Added
Goldman Sachs Group Inc176,261$530.5K0.00%+1,279+0.7%Added
ADAR1 Capital Management, LLC163,078$490.9K0.08%+163,078New
BML Capital Management, LLC150,000$451.5K0.27%00.0%Unchanged
State Street Corp88,708$267.0K0.00%00.0%Unchanged
Blair William & Co88,466$266.3K0.00%00.0%Unchanged
AdvisorShares Investments LLC67,780$204.0K0.04%+16,000+30.9%Added
Two Sigma Investments, LP61,542$185.2K0.00%−5,969−8.8%Reduced
Susquehanna International Group, LLP52,094$156.8K0.00%−13,013−20.0%Reduced
Northern Trust Corp49,431$148.8K0.00%−531−1.1%Reduced
Valence8 US LP34,376$103.5K0.05%+34,376New
American Century Companies Inc30,197$90.9K0.00%−118−0.4%Reduced
Squarepoint Ops LLC27,575$83.0K0.00%+16,180+142.0%Added
Millennium Management LLC25,337$76.3K0.00%+25,337New
Charles Schwab Investment Management Inc23,302$70.1K0.00%00.0%Unchanged
Simplex Trading, LLC23,000$69.0K0.00%+5,893+34.4%Added
HighTower Advisors, LLC20,828$64.0K0.00%+20,828New
Virtu Financial LLC20,210$61.0K0.00%+4,722+30.5%Added
Kestra Advisory Services, LLC20,033$60.3K0.00%+20,033New
Jane Street Group, LLC19,659$59.2K0.00%+19,659New
Advisor Group Holdings, Inc.10,226$30.8K0.00%−800−7.3%Reduced
UBS Group AG10,121$30.5K0.00%−9,145−47.5%Reduced
Morgan Stanley5,319$16.0K0.00%−547−9.3%Reduced
Royal Bank of Canada4,501$14.0K0.00%+3,420+316.4%Added
Caption Management, LLC4,460$13.4K0.00%+4,460New
CWM, LLC2,416$7.00K0.00%00.0%Unchanged
Tower Research Capital LLC (TRC)2,259$6.80K0.00%−225−9.1%Reduced
Bank of America Corp1,810$5.45K0.00%+1,572+660.5%Added
Citigroup Inc1,229$3.70K0.00%+1,226+40,866.7%Added
BFSG, LLC1,000$3.01K0.00%00.0%Unchanged
SJS Investment Consulting Inc.100$3010.00%00.0%Unchanged
Jones Financial Companies LLLP80$2460.00%00.0%Unchanged
Farther Finance Advisors, LLC81$2440.00%00.0%Unchanged
Fairman Group, LLC29$870.00%00.0%Unchanged
FMR LLC25$750.00%−4,121−99.4%Reduced
JPMorgan Chase & Co16$480.00%00.0%Unchanged
Armistice Capital, LLC0$00.00%−300,000−100.0%Sold out
Barclays PLC0$00.00%−19,261−100.0%Sold out
Qube Research & Technologies Ltd0$00.00%−492−100.0%Sold out
BlackRock Inc.––––Not filed